Search Share Prices
SkinBioTherapeutics makes new patent filing for SkinBiotix
AIM-quoted life sciences company SkinBioTherapeutics has made a new patent filing for its SkinBiotix product.
SkinBiotix, designed to increase filaggrin levels in the skin, has been shown to significantly improve both the surface and inner layers of skin, suggesting that the technology will be "therapeutically useful" in a range of conditions, such as eczema.
The patent application follows a second successful test of SkinBiotix that proved the product can increase the "tight junction" within the inner layer of human skin.
Dr Cath O'Neill, SkinBioTherapeutics' chief executive, said, "SkinBiotix is continuing to prove its uniqueness as a platform via scientific testing. Following the successful work in skin models on fillagrin production, we are looking to increase the value and scope of our intellectual property with the filing of this patent."
"This is a continuation of our strategy to create an IP portfolio that allows us to robustly protect what we believe is a technology of significant commercial value in key global dermatological markets," O'Neill added.
As of 1010 BST, SkinBio shares had grown 3.44% to 16.55p.